<DOC>
	<DOCNO>NCT02151695</DOCNO>
	<brief_summary>Proliferative diabetic retinopathy serious complication diabetes mellitus , partly consecutive upregulation vascular endothelial growth factor ( VEGF ) consequence retinal ischemia lead . Aflibercept approve FDA European medicine agency treatment exudative age-related macular degeneration , another retinal disease characterize choroidal new vessel . The aim pilot study evaluate efficacy safety Aflibercept intravitreal injection compare panretinal photocoagulation proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Safety Efficacy Aflibercept Proliferative Diabetic Retinopathy .</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Patients diabetes mellitus type 1 type 2 complicate PDR Male female 18 year HbA1c &lt; 11 % study entry Systolic blood pressure &lt; 160 mmHg diastolic blood pressure &lt; 105 mmHg study entry Backgrounds clear eye , pupil dilation patient cooperation sufficient allow examination fundus photograph good quality Hypersensitivity aflibercept excipients History retinal laser ( macular panretinal photocoagulation ) , intravitreal injection , vitrectomy eye study PDR associate tractional retinal detachment eye study PDR associate fibrovascular proliferation eye study Florid diabetic retinopathy Eye infection periocular active suspect Unbalanced glaucoma eye study Other eye disease eye study Patients significant medical problem may interfere evaluation safety efficacy treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>